Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks

  • 📰 CNBC
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 72%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

For years, biopharma investors put a lot of focus on companies that were involved in oncology and immunology research. But interest is shifting to other areas.

As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. "Our analysis shows Genetic Medicine and Metabolic outperformed by > 20% on average over the ~5.

In July, the Food and Drug Administration could grant full approval to Leqembi , its Alzheimer's Disease treatment. That could then prompt the Centers for Medicare and Medicaid Services to agree to reimburse patients for the treatment, which could cost Medicare as much as $5 billion per year, a recent study published in JAMA Internal Medicine found .

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in NG

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines